RTP oncology firm G1 strikes 3rd licensing deal in 3 months, latest one being worth up to $170M

RESEARCH TRIANGLE PARK – G1 Therapeutics has struck another development deal for its oncology portfolio, the latest one announced Monday being worth as much as $170 million plus future royalties.

In the last three months, G1 has now made three deals that could mean substantial revenues.

The latest deal is with China-based Simcere Pharmaceutical Group for trilaciclib, a potential aimed at helping people recover from chemotherapy. It calls for an upfront payment of $14 million, another $156 million in milestone payments plus royalties.

“Trilaciclib has the potential to be the first proactively administered myelopreservation therapy that can improve outcomes for patients receiving chemotherapy. We are excited to collaborate with Simcere, an established leader in innovative drug development and commercialization in China, to advance this new therapy in China,” said Mark Velleca, Chief Executive Officer of G1, in Monday’s announcement.

“Simcere has extensive experience conducting clinical trials and securing regulatory approvals in China, and an expansive commercial infrastructure that supports education and access. These strengths make them an important strategic partner for G1 to achieve our vision of bringing trilaciclib to patients around the world.”

For G1’s two other recent deals, see these links: